The detailed program can be downloaded here. In plenary sessions, German and French diabetes scientists will present the highlights of diabetes research as well as the work of the DZD and of INSERM/AVIESAN (Institute of Health and Medical Research/ Alliance for Life Sciences and Health). A panel discussion with representatives from science, policy making and industry will illuminate the challenge of translational diabetes research, cooperation between industry and science as well as the political conditions for research in Germany and France. A joint networking dinner on December 11th will offer the opportunity for exchange.
The high-profile event was initiated by the French Embassy to promote German-French exchanges in the field of diabetes research. “Given the increasing number of diabetic patients, there is an urgent need to curb this widespread disease. It is important to bring together outstanding researchers, industrial partners and policy representatives in order to find new ways of diabetes prevention and treatment,” said Prof. Dr. Günther Wess, scientific director of Helmholtz Zentrum München, which is a partner in the DZD. A first step has been the establishment of the Franco-German Diabetes Academy, in which young German and French scientists collaborate on important topics of diabetes research. This initiative is supported by the BMBF, INSERM/AVIESAN and Sanofi.
The German Center for Diabetes Research (DZD) was founded in 2009 by the Federal Ministry for Education and Research (BMBF) as a national research association. More than 250 scientists from basic and clinical research are working closely in six research programs, thus enabling a timely implementation of the research results. The aim of all research work of the DZD is to develop individualized prevention strategies and effective, personalized therapies.
The members of the DZD are Helmholtz Zentrum München – German Research Center for Environmental Health, the German Diabetes Center (DDZ) in Düsseldorf, the German Institute of Human Nutrition (DifE) in Potsdam-Rehbrücke, the Paul Langerhans Institutes of the University of Dresden and the University of Tübingen as well as associated partners at the universities in Heidelberg, Cologne, Leipzig, Lübeck and Munich. www.dzd-ev.de
The French National Alliance for Life Sciences and Health (AVIESAN) was founded in April 2009. The aim was to improve the performance of French research through improved coherence and the promotion of creativity and excellence. The most important stakeholders of life and health sciences are united in the alliance. The tasks of AVIESAN encompass the coordination of strategic analyses, the scientific program planning and the operative implementation of research in the areas of the life sciences and health, the acceleration of the knowledge transfer from basic research into clinical applications, the promotion of transdisciplinarity, ensuring the clinical, economic and social utilization of knowledge, in particular by promoting industrial partnerships, the definition of common positions in European research and international cooperation as well as harmonization and simplification of administrative procedures for laboratories, in order to give research teams greater leeway for creativity and excellence. The founding members of the alliance are: INSERM, Institut Pasteur, the National Centre for Scientific Research (CNRS), the French Alternative Energies and Atomic Energy Commission (CEA), Lille Regional University Hospital CHRU, the Conference of University Presidents (CPU), the National Institute of Research in Informatics and Automatics (INRIA) and the Institute for Research and Development (IRD). http://www.aviesan.fr/en
Founded in 1964, the French National Institute of Health and Medical Research (INSERM) is a public scientific and technological institute dedicated to research in biomedicine and in public health. As interface between research laboratories and the patient, INSERM implements multidisciplinary, cutting-edge research programs to investigate human diseases. http://www.inserm.fr/
Sanofi is a global healthcare leader focused on patients’ needs which is engaged in the research, development and marketing of therapeutic solutions. Sanofi has core strengths in healthcare, with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi shares are listed on the stock exchanges of Paris (EURONEXT: SAN) and New York (NYSE: SNY).
The Office for Science and Technology of the French Embassy in Germany is dedicated to bilateral French-German collaborations in Science and Technology. http://www.wissenschaft-frankreich.de/de/
Free registration at www.dzd-ev.de
Dr. Astrid Glaser, German Center for Diabetes Research
Head Office at Helmholtz Zentrum München
Ingolstädter Landstr. 1, 85764 Neuherberg
Marie de Chalup, French Embassy
Section for Partnerships and Communication
Office for Science and Technology
Phone: +49(0)30-590 03 92 62 / -63